Summary: Iodine-123 (I-123) is a radioactive isotope frequently employed in nuclear medicine to help diagnose and monitor thyroid conditions and other disorders. This article explores its physical properties, production methods, mechanism of action, clinical applications, advantages, limitations, safety measures, and prospective developments within the field.
Keywords: I-123; Nuclear medicine; Thyroid imaging; Gamma camera; SPECT; Radioisotope.
Introduction to Iodine-123
Iodine-123 (I-123) holds a key position in nuclear medicine, where it is primarily used for diagnostic imaging. Medical practitioners value this isotope for its favourable physical characteristics and its capacity to provide detailed information regarding the function of various organs, with the thyroid gland being the most common target. Since the thyroid accumulates iodine as part of its normal functioning, isotopes such as I-123 can be employed to detect irregularities in hormone production, cellular metabolism, and other underlying processes.
Radiopharmaceuticals rely on radioisotopes that emit radiation that is detectable by imaging devices such as gamma cameras or single-photon emission computed tomography (SPECT) systems. I-123 is especially useful in this context because of its relatively short half-life (13.2 hours) and its emission of gamma rays at an energy level that is suitable for high-quality images. When administered to a patient, I-123-containing radiopharmaceuticals localise in thyroid tissue (or other specific tissues, depending on the chemical form), enabling healthcare professionals to visualise functional activity in real-time.
Thyroid disorders, including hyperthyroidism, hypothyroidism, and thyroid nodules, are extremely prevalent in the general population. Swift and accurate diagnosis is important for effective patient management, and I-123 imaging has become an essential tool in this process. While I-131 (another iodine isotope) also has diagnostic and therapeutic capabilities, I-123 remains preferred for many purely diagnostic studies due to its lower radiation dose, clearer images, and reduced harm to surrounding tissue.
The purpose of this article is to explore the important characteristics of I-123, the ways in which it is generated for clinical use, its mechanism of action in diagnostic procedures, its advantages in comparison with other isotopes, and the current measures in place for safety and regulation. In addition, it will consider emerging trends and research that might shape the future applications of this radioisotope.
By the end, readers should have a deeper insight into how I-123 assists healthcare providers in diagnosing thyroid disorders and other conditions. This understanding fosters an appreciation for the balance between scientific innovation and the need to protect patients, healthcare workers, and the public from the hazards associated with ionising radiation.
Physical Properties and Production
I-123 is a radioactive isotope of the element iodine. Its nuclear composition enables it to decay primarily through electron capture, emitting gamma photons that are useful for medical imaging. The predominant gamma emission of I-123 is approximately 159 keV, which falls into an energy range well suited for gamma camera detectors, allowing for precise imaging of target tissues.
The half-life of I-123 is 13.2 hours. This timeframe makes it long enough for most diagnostic tests (which generally take place within a single day), while simultaneously short enough to reduce radiation exposure to the patient and the environment. Because the radioactivity diminishes relatively quickly, patient safety is improved when compared to isotopes with longer half-lives.
Methods of Production
I-123 is most commonly produced through cyclotron bombardment of enriched xenon or through certain nuclear reactor processes. In a typical cyclotron-based production route, enriched xenon-124 gas is bombarded with protons. The nuclear reactions that occur subsequently form I-123. The radioactive iodine is then chemically extracted and purified to meet strict clinical standards, ensuring that it is safe for patient administration.
Another production method involves neutron irradiation of tellurium-122 or tellurium-123 in research reactors. However, the cyclotron method is preferred in many facilities because it can yield material with fewer radioactive by-products, which simplifies purification. Moreover, the cyclotron approach can be located relatively close to medical centres, meaning that the isotope can be transported rapidly to the hospital or clinic for use before significant decay occurs.
Chemical Forms
Once produced, I-123 is processed into a variety of radiopharmaceuticals. A common form is sodium iodide (NaI), which the thyroid gland absorbs in a manner similar to stable (non-radioactive) iodine. Other labelled compounds might target different tissues or metabolic pathways, allowing medical practitioners to evaluate various organs and physiological processes. Regardless of the form, radiopharmaceuticals must be rigorously tested for sterility, purity, and appropriate radioactive concentration.
Quality Assurance and Purity
Given the importance of accuracy in diagnostic imaging, it is paramount to maintain stringent quality control measures. The production facility must verify the radionuclidic purity of I-123, ensuring minimal contamination from iodine-124, iodine-125, and iodine-130, among other isotopes. These impurities could affect image quality or unnecessarily increase the radiation dose to the patient. Furthermore, chemical purity must be confirmed so that no harmful substances remain after production. Quality assurance protocols typically involve gamma spectrometry, radiochemical tests, and checks for pH, sterility, and endotoxins.
Mechanism of Action in Diagnostic Imaging
The human body requires iodine to synthesise thyroid hormones (namely thyroxine (T4) and triiodothyronine (T3)). The thyroid gland actively transports iodine from the bloodstream into its tissue via sodium-iodide symporters. This means that if I-123 is administered to a patient, the thyroid will absorb the radioactive iodine in much the same way that it would absorb stable iodine.
As the thyroid cells continue to function, they distribute iodine among various steps of hormone production. If a patient has a condition such as Graves’ disease or a toxic multinodular goitre, the rate of iodine uptake might be higher than normal, producing a strong signal on nuclear medicine scans. Conversely, a low uptake might reflect a different type of thyroid dysfunction, such as thyroiditis.
Gamma Emission and Detection
After entering the thyroid gland (or any other target tissue relevant to the radiopharmaceutical’s design), I-123 undergoes radioactive decay predominantly by electron capture. The nucleus of I-123 captures an orbital electron, and this process leaves the nucleus in an excited state. As it returns to the ground state, gamma photons at approximately 159 keV are emitted.
These gamma rays escape the patient’s body and can be detected by a gamma camera or a SPECT scanner. Gamma cameras use scintillation crystals (commonly sodium iodide crystals doped with thallium) to convert the incoming gamma photons into visible light. Photomultiplier tubes then detect and amplify these light signals, and a computer reconstructs an image indicating the distribution of I-123 within the body. With SPECT, the scanner rotates around the patient to collect data from multiple angles, allowing for a three-dimensional representation of the isotope’s distribution.
Image Reconstruction and Analysis
The quality of the image depends on:
- The energy of the gamma emission, 159 keV, is ideal for many detectors.
- The energy resolution of the detection system.
- The collimator design helps focus and discriminate the incoming gamma rays.
Data from the gamma camera or SPECT system is processed to generate images that a nuclear medicine specialist or radiologist can interpret. Areas of high activity (referred to as “hot spots”) might indicate hyperfunctioning thyroid nodules, while areas of low activity (“cold spots”) suggest possible cancerous nodules or regions of diminished function.
Use in Non-Thyroid Imaging
Although I-123 is strongly associated with thyroid imaging, it can also be incorporated into other compounds for imaging the brain, adrenal glands, or cardiac tissues. For instance, I-123 metaiodobenzylguanidine (MIBG) is widely used to evaluate adrenal tumours (phaeochromocytomas) or neuroendocrine tumours such as neuroblastoma. The mechanism of action here still relies on gamma emission and detection, but the molecular structure of the radiopharmaceutical directs I-123 to specific receptors or biological processes beyond the thyroid.
Clinical Applications of I-123
A typical use of I-123 is the thyroid uptake and scan procedure. Patients ingest a calibrated dose of sodium iodide I-123, typically in capsule form. After a specified interval (usually 4–6 hours, with a second measurement at around 24 hours), a gamma probe is positioned over the patient’s thyroid region to measure how much of the administered dose has been taken up by the gland. Simultaneously, imaging can be performed with a gamma camera to visualise the distribution of the radioactive iodine.
The information gained from these tests includes:
- The overall percentage of uptake can help differentiate between various causes of hyperthyroidism (e.g., Graves’ disease vs. thyroiditis).
- The presence or absence of functional nodules within the gland.
- The relative function of different regions within the thyroid.
Hyperthyroidism
Hyperthyroidism encompasses conditions in which the thyroid gland produces too much hormone. Graves’ disease is a common cause, leading to diffuse hyperactivity throughout the thyroid. Toxic multinodular goitre and toxic adenomas represent other scenarios where certain nodules become hyperactive. By administering I-123 and performing an uptake scan, healthcare professionals can determine whether the entire gland is overactive or if just specific nodules are the culprit. This helps guide treatment decisions, such as antithyroid medications, radioactive iodine ablation therapy (often with I-131), or surgery.
Thyroid Cancer
Although I-131 has a more prominent role in thyroid cancer management (particularly for ablation of residual thyroid tissue), I-123 can assist in diagnostic imaging to locate metastatic lesions or to evaluate how much thyroid tissue remains after surgery. Many clinicians use I-123 scanning as a preparatory step before deciding on therapeutic doses of I-131 because the imaging properties of I-123 are superior for detecting smaller areas of functioning thyroid tissue.
MIBG Scans
Beyond the thyroid, I-123 is attached to metaiodobenzylguanidine (MIBG) for scanning neuroendocrine tumours. Neuroendocrine cells have the ability to take up and store certain amines or amine precursors, which MIBG mimics structurally. Therefore, tumours such as phaeochromocytomas or neuroblastomas might accumulate I-123 MIBG, allowing for localisation and assessment of disease spread. This technique can be essential for treatment planning, as it reveals the extent of metastatic disease that might not be apparent in other imaging modalities.
Neurological Imaging
I-123 can be incorporated into radiopharmaceuticals designed for brain imaging. Examples include I-123 ioflupane (DaTscan), which is used to assess dopamine transporters in the basal ganglia for suspected Parkinsonian syndromes. By visualising the distribution of I-123 ioflupane, clinicians can differentiate Parkinson’s disease or Parkinson-plus syndromes from essential tremor or other movement disorders.
Cardiac Imaging
In some instances, I-123-labelled compounds can be used to evaluate cardiac innervation or myocardial perfusion. Though not as ubiquitous as technetium-99m or thallium-201 in nuclear cardiology, I-123 agents provide valuable functional data under certain circumstances, for example, in investigating cardiac sympathetic innervation in heart failure or arrhythmias.
Advantages and Limitations
Advantages of I-123
- Ideal Gamma Energy: The gamma energy of 159 keV is well matched to the sensitivity and resolution of common gamma cameras, enabling the production of high-quality images.
- Short Half-Life: The 13.2-hour half-life allows sufficient time for imaging protocols to be carried out while also reducing overall radiation exposure to the patient. This characteristic enhances patient safety compared with isotopes that remain radioactive within the body for longer periods.
- Reduced Radiation Dose: The electron capture decay process in I-123 generally results in fewer beta emissions, which can be damaging to tissues. Consequently, patients receive a lower radiation dose than with certain other radioisotopes, such as I-131.
- Diagnostic Accuracy: For thyroid imaging, I-123 often yields clearer and more diagnostically useful images than I-131, making it the preferred choice for many routine evaluations.
- Versatility: I-123 can be incorporated into a variety of radiopharmaceuticals, enabling imaging of different organs and conditions, including neuroendocrine tumours and neurological disorders.
Limitations of I-123
- Cost and Availability: Producing I-123 can be expensive and requires specialised equipment (cyclotrons or nuclear reactors). Additionally, the short half-life means distribution logistics must be well organised, limiting availability in areas without accessible production facilities.
- Competition from Other Radioisotopes: In some clinical scenarios, technetium-99m may be preferred due to its lower cost, ready availability, and similarly favourable imaging characteristics.
- Potential for Contamination: The production process can lead to impurities such as I-124 or I-125, which may persist longer and increase radiation dose. Facilities must maintain high-quality control to avoid this issue.
- Limited Therapeutic Use: I-123 is almost exclusively diagnostic. While its decay properties are useful for imaging, it lacks the strong beta emissions that make I-131 effective for therapeutic applications such as thyroid cancer ablation. As a result, I-123 cannot replace I-131 in those clinical settings.
- Regulatory and Handling Requirements: Although less radioactive than some alternatives, I-123 is still a radioactive substance. Its handling and disposal must adhere to strict guidelines to protect healthcare workers and the public, which can complicate medical protocols and infrastructure.
Safety, Handling, and Regulations
When working with radioactive materials, healthcare facilities must adhere to the core principles of radiation protection: time, distance, and shielding. Reducing the time spent near the radioactive material, increasing the distance from it, and using appropriate shielding (e.g., lead containers or protective barriers) all minimise radiation exposure.
Healthcare workers who handle I-123 follow standard procedures such as wearing dosimeters to track their exposure, using protective clothing, and staying behind protective screens when possible. Institutions must monitor these safety measures, and regular audits are usually performed to ensure ongoing compliance.
Storage and Transport
Storage areas for radiopharmaceuticals require careful planning. I-123 is typically stored in shielded containers to contain the gamma emissions. Because of the short half-life, inventory management must be precise: the isotope needs to be used quickly after delivery. Transporting I-123 also demands adherence to regulations imposed by local or international authorities, who set guidelines on packaging, labelling, and documentation to ensure safety during transit.
Patient Safety
Before administering I-123 to a patient, medical professionals must confirm that the individual does not have any contraindications. For example, pregnant or breastfeeding women may require alternative imaging strategies unless the benefits of the procedure clearly outweigh the risks. Patients should also be educated on any temporary dietary or medication restrictions, as excess stable iodine intake can reduce the thyroid’s uptake of I-123 and compromise image quality.
After the procedure, minimal precautions are typically required because of I-123’s relatively low radioactive burden. Patients are generally instructed to maintain good hygiene (flushing the toilet twice, washing hands thoroughly) to minimise radiation exposure to others through bodily fluids. However, these measures are much less strict than those associated with longer-lived isotopes.
Regulatory Bodies
Various organisations oversee the use of radioactive materials in medicine. In the United Kingdom, the use of I-123 is regulated by agencies such as the Environment Agency, the Health and Safety Executive, and the Medicines and Healthcare products Regulatory Agency (MHRA). These bodies ensure that facilities meet standards for radiation safety, quality control, and patient protection. Internationally, the International Atomic Energy Agency (IAEA) sets guidelines and recommendations that many countries adopt, in conjunction with local regulations.
Disposal of Radioactive Waste
Radioactive waste from I-123 procedures includes used syringes, vials, and any residual isotope that is not administered to the patient. Because of its short half-life, much of this waste can be stored until the radioactivity decays to a safe level, after which it can be disposed of through normal hospital waste protocols. Strict record-keeping ensures transparency and compliance with regulations governing the disposal of radioactive material.
Future Outlook
Technological progress in imaging hardware and software may enhance the role of I-123 in clinical practice. Improved gamma cameras, SPECT/CT hybrid systems, and image processing algorithms allow for better spatial resolution, faster scan times, and more accurate delineation of pathological processes. The continued development of new radiopharmaceuticals that harness the imaging properties of I-123 could broaden its range of diagnostic applications and include molecular pathways that had previously not been evaluated.
Personalised Medicine
Nuclear medicine already leans towards precision by targeting specific metabolic or receptor pathways. I-123-based imaging might experience further expansion if new compounds are engineered to bind to particular disease markers, potentially supporting a personalised approach. For instance, investigators might create I-123 radiotracers specific to certain cancer cells or neurological pathways. This would allow clinicians to identify diseases at an earlier stage and tailor treatment plans to the individual’s biochemical profile.
Combination Therapies
Although I-123 itself is not primarily used for therapy, the imaging data it provides could help clinicians optimise therapeutic strategies, possibly in conjunction with other isotopes like I-131 or lutetium-177 for targeted treatments. Such synergy might lead to protocols where I-123 imaging precisely identifies disease extent and function, guiding a targeted treatment with another radioisotope that delivers a higher therapeutic dose.
Production Innovations
Research into alternative methods of producing I-123 may reduce costs and streamline availability. More efficient cyclotron designs, improved target materials, and advanced purification strategies could bolster production yields while minimising radioactive waste. This progress could make I-123 more accessible worldwide, ultimately enhancing patient care and expanding the global reach of nuclear medicine.
Regulatory Considerations
As the applications of nuclear medicine evolve, regulatory frameworks must adapt. Ongoing discussions focus on refining guidelines to incorporate new isotopes, novel imaging protocols, and emerging technology. By maintaining rigorous safety standards and consistently updating protocols, regulatory bodies can ensure that the benefits of I-123 imaging extend to as many patients as possible without compromising safety.
Conclusion
Iodine-123 (I-123) has proven itself as a crucial radioisotope for diagnostic imaging, both within thyroid medicine and across a growing range of clinical applications. Its favourable properties—such as the 13.2-hour half-life and gamma emission at 159 keV—enable it to generate high-quality scans with a relatively modest radiation burden. Whether in the assessment of thyroid function, the detection of neuroendocrine tumours, or the investigation of neurological disorders, I-123 provides clinicians with detailed functional data that often surpasses the anatomical information gleaned from other imaging modalities alone.
Producing and handling I-123 comes with challenges linked to cost, logistics, and adherence to radiation safety requirements. Nonetheless, careful quality control ensures that impurities are kept to a minimum, and robust safety regulations safeguard both patients and healthcare personnel. When used according to strict clinical guidelines, I-123 significantly aids in accurate disease diagnosis and monitoring, which ultimately improves patient outcomes.
As imaging technology continues to evolve and personalised approaches gain traction, new I-123-labelled radiopharmaceuticals could appear, targeting previously unexplored biochemical pathways. Research might also enhance the efficiency of I-123 production, allowing broader, more affordable access. In this way, I-123 may play an even larger role in the future of nuclear medicine, contributing to earlier detection, more precise characterisation of disease, and better-tailored therapeutic plans.
Iodine-123 remains a mainstay in nuclear medicine due to its unique attributes, balancing clinical effectiveness with patient and worker safety. Its continued evolution aligns with the broader goals of healthcare to provide accurate, individualised, and minimally invasive diagnostic methods. Through dedicated research, technological innovation, and responsible regulatory oversight, I-123 is set to maintain—and potentially expand—its position as an indispensable tool in modern medical imaging.
Disclaimer
The information provided in this article, Iodine-123: A Key Radioisotope in Nuclear Medicine, is intended for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Readers should not rely solely on the content herein for decisions regarding health or medical care. Any individual requiring medical attention should consult a qualified healthcare professional or specialist in nuclear medicine.
While every effort has been made to ensure accuracy, the authors and publishers make no warranties or representations regarding the completeness, reliability, or suitability of the information. Use of radioactive materials such as iodine-123 is strictly regulated and should only be undertaken by trained professionals in approved medical or research facilities. The authors and publishers accept no responsibility for any consequences arising from the use or misuse of the information contained in this article.
You are here: home »